Overview

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

Status:
Completed

Trial end date:
2012-08-01

Target enrollment:

Participant gender:

Summary

A multicenter, 8-week study to evaluate the efficacy of 2 doses (50 and 100 mg/day) of desvenlafaxine succinate sustained-release (DVS SR) versus placebo in adult outpatients with major depressive disorder.

Phase:

Phase 4

Details

Lead Sponsor:

Pfizer

Treatments:

Desvenlafaxine Succinate